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Introduction: We evaluated treatment patterns of elderly patients 
with stage IIIA (N2) non–small-cell lung cancer (NSCLC).
Methods: The use of surgery, chemotherapy, and radiation for 
patients with stage IIIA (T1-T3N2M0) NSCLC in the Surveillance, 
Epidemiology, and End Results–Medicare database from 2004 to 
2007 was analyzed. Treatment variability was assessed using a mul-
tivariable logistic regression model that included treatment, patient, 
tumor, and census track variables. Overall survival was analyzed using 
the Kaplan–Meier approach and Cox proportional hazard models.
Results: The most common treatments for 2958 patients with stage 
IIIA (N2) NSCLC were radiation with chemotherapy (n = 1065, 
36%), no treatment (n = 534, 18%), and radiation alone (n = 383, 
13%). Surgery was performed in 709 patients (24%): 235 patients 
(8%) had surgery alone, 40 patients (1%) had surgery with radia-
tion, 222 patients had surgery with chemotherapy (8%), and 212 
patients (7%) had surgery, chemotherapy, and radiation. Younger age 
(p < 0.0001), lower T-status (p < 0.0001), female sex (p = 0.04), and 
living in a census track with a higher median income (p = 0.03) pre-
dicted surgery use. Older age (p < 0.0001) was the only factor that 
predicted that patients did not get any therapy. The 3-year overall 
survival was 21.8 ± 1.5% for all patients, 42.1 ± 3.8% for patients that 
had surgery, and 15.4 ± 1.5% for patients that did not have surgery. 
Increasing age, higher T-stage and Charlson Comorbidity Index, and 
not having surgery, radiation, or chemotherapy were all risk factors 
for worse survival (all p values < 0.001).
Conclusions: Treatment of elderly patients with stage IIIA (N2) 
NSCLC is highly variable and varies not only with specific patient 
and tumor characteristics but also with regional income level.
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(J Thorac Oncol. 2013;8: 744-752)
Stage IIIA non–small-cell lung cancer (NSCLC) encom-passes a heterogeneous group of patients, including T4N0, 
T3-4N1, and T1-3N2.1 Patients in the subset due to N2 lymph 
node metastases represent approximately 10% of all patients 
diagnosed with NSCLC.2 Multimodality therapy with some 
combination of surgical resection, chemotherapy, and radia-
tion therapy is the preferred approach for patients with stage 
IIIA (N2) NSCLC, but the optimal management strategy has 
not been definitively established by randomized controlled 
data.3–7 In particular, the benefit of surgery when radiation and 
chemotherapy have been used is unclear.8–10 Induction chemo-
therapy and radiation therapy followed by surgical resection 
for patients with stage IIIA disease is feasible but may only 
provide survival benefit to selected patients.11
Treatment guidelines reflect the lack of available defini-
tive evidence for this stage of NSCLC. Guidelines such as those 
from the National Comprehensive Cancer Network (NCCN) 
recognize the need for local therapy in addition to systemic 
therapy but do not explicitly specify the role of surgery ver-
sus radiation therapy.12 NCCN treatment recommendations 
for patients pathologically confirmed to have N2 lymph node 
involvement but not distant metastatic disease include both 
definitive concurrent chemoradiation and induction chemother-
apy followed by surgery if repeat staging does not demonstrate 
disease progression. The NCCN also recommends consider-
ation of radiation therapy either before or after surgery and addi-
tional chemotherapy after surgery. Considering the lack of clear 
data and guidelines that allow several options for treatment, 
the combination and timing of treatment modalities may have 
significant variability in clinical practice. Treatment may also 
vary according to specific patient characteristics, considering 
that disparities in overall lung cancer treatment and prognosis 
are known to exist for race, socioeconomic status, educational 
status, and geographical location.13–26 This study was designed 
to examine patterns of care for elderly patients with stage IIIA 
(N2) NSCLC in a national database and test the hypothesis that 
nonclinical characteristics play an important role in whether 
surgery is performed for patients. We focused on examining 
characteristics and outcomes associated with surgery to attempt 
to understand how patients are selected for surgery in this set-
ting, as randomized trials have failed to definitively show a sur-
vival advantage to performing surgical resection in patients that 
are treated with chemotherapy and radiation.10,11
PATIENTS AND METHODS
This study was performed with approval by the Duke 
University Institutional Review Board. A retrospective cohort 
study of patients diagnosed with NSCLC was conducted 
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using the Survival, Epidemiology, and End Results (SEER)–
Medicare database, which brings together Medicare adminis-
trative claims data with detailed clinical tumor registry data 
in a representative sample covering approximately 14% of 
the U.S. population across a wide geographic variation.27 The 
SEER-Medicare database was initially queried to identify 
patients with lung cancer from the years 2004 to 2007. The 
analysis was limited to the years 2004–2007 to allow appro-
priate identification of the patients of interest (T1-3N2M0), 
because earlier data in the database provided overall stage but 
did not provide detailed tumor, node, and metastasis status to 
allow identification of patients who were stage IIIA due to N2 
lymph node status. In SEER, the reported stage is the patho-
logic stage for patients who did not receive any pre resection 
treatment. The reported stage is the clinical stage for patients 
who do not undergo resection or who receive any neo-adju-
vant treatment before resection.
From the entire lung cancer cohort, patients aged 65 
years or older and definitively identified as having a NSCLC 
histologic type were selected. Patients younger than 65 years 
were excluded because these patients in the Medicare data 
consist of individuals who are disabled or have end-stage 
renal disease. Only patients who had both continuous Part A 
and Part B Medicare coverage with no health maintenance 
organization enrollment at all between 1 year before and 6 
months after diagnosis, or until the month of death for patients 
who died within 6 months of diagnosis, were included in the 
analysis, to minimize the chance that our analysis could fail 
to capture treatment because of non-Medicare coverage. This 
requirement that patients had continuous Medicare cover-
age for 1 year before diagnosis effectively meant that only 
patients aged 66 years or older at the time of diagnosis were 
included in the analysis. In addition, we excluded patients who 
did not have a lung cancer diagnosis code in their Medicare 
claims within 2 months before and 3 months after the date 
of their lung cancer diagnosis in SEER, because of concerns 
that treatment information derived from the Medicare records 
was potentially inaccurate due to the discrepancy between the 
lung cancer identified in SEER but seemingly not confirmed 
in Medicare. For each patient, the Charlson Comorbidity 
Index was measured at the date of diagnosis using Medicare 
records during a year before the date of diagnosis according 
to specifications previously described.28,29 Patients were iden-
tified as having received surgery, radiation, and chemother-
apy if there was at least one indicator of treatment within 6 
months of diagnosis in the Medicare Provider Analysis and 
Review, Outpatient Claims, Durable Medical Equipment and 
Carrier Claims Medicare files using Health Care Common 
Procedure Coding System codes, International Classification 
of Diseases, Ninth Revision (ICD-9) diagnosis and proce-
dure codes, Current Procedural Terminology codes, Revenue 
Center Codes, and Diagnostic-Related Group Codes as pre-
viously described (Supplemental Tables 1–3, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A407).30–33 The 
date of onset of chemotherapy was identified using methods 
originally developed for date of disease onset.34
Method of mediastinal staging was assessed as follows. 
We used the inpatient, outpatient, and physician Medicare 
claims to search for Current Procedural Terminology or Health 
Care Common Procedure Coding System codes for computed 
tomography scan, positron emission tomography (PET) scan, 
mediastinoscopy, mediastinotomy, endobronchial ultrasound, 
endoscopic ultrasound, or video-assisted thoracoscopic sur-
gery biopsies (Supplemental Table 4, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A407). Patients were 
considered to have invasive mediastinal staging if they had 
mediastinoscopy, mediastinotomy, endobronchial ultrasound, 
endoscopic ultrasound, or a video-assisted thoracoscopic 
biopsy. We searched for mediastinal staging procedures per-
formed 3 months before diagnosis through the initiation of 
treatment or for 3 months after diagnosis in the case of patients 
who were not treated with any cancer-specific therapy.
Both univariate- and multivariable-adjusted logistic 
regression analyses were performed relating surgery use to the 
following patient characteristics: age, T-stage, sex, race (black 
versus others), comorbidities, and the following informa-
tion from the patient’s census tract based on the 2000 census 
bureau survey: median income, percentage of blacks, percent-
age of persons 25 years or older with at least 4 years of college 
education, and percentage of residents living below the pov-
erty level. Similar logistic regression analysis relating the use 
of any therapy with the same variables was also performed. 
Survival analyses were performed both with the Kaplan–Meier 
method comparing survival curves with the log-rank test and 
with the multivariate-adjusted Cox proportional hazard model 
that included age, T-stage, the Charlson comorbidity index, 
and treatment with surgery, chemotherapy, and radiation. A 
similar survival analysis was repeated on a subset of patients 
that included only those patients who received some local 
therapy in the form of either surgery or radiation.
Unpaired Student’s t tests were used to compare con-
tinuous data, and χ2 for categoric variables. A two-tailed p 
value of less than 0.05 was considered significant. Data are 
presented as counts (%), mean (SD), OR, or hazard ratios 
(HR) (95% confidence intervals) where appropriate. The SAS 
9.2 statistical package (SAS Institute, Cary, NC) was used for 
statistical analyses.
RESULTS
Initially, 136,699 individuals with lung cancer from 
2004 to 2007 were identified in the database, of whom 82,062 
were 65 years or older with non–small-cell histology. Of 6350 
patients aged 65 years or older and stage IIIA (N2) NSCLC, 
2958 patients who met all inclusion criteria were identified. 
The details of treatment are listed in Table 1. Treatment was 
quite variable, and there was not a single dominant treatment 
regimen. The most common treatments were radiation with 
chemotherapy (n = 1065, 36%), no treatment (n = 534, 18%), 
and radiation alone (n = 383, 13%). Overall, treatment included 
surgery, radiation, and chemotherapy in 212 patients (7%), 
two of these modalities in some combination in 1327 patients 
(45%), and only one of these modalities in 885 patients (30%).
Most patients received some form of local therapy with 
either surgery or radiation, although 801 patients (27%) did 
not receive local treatment, with 267 patients (9%) being 
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treated with chemotherapy alone. Chemotherapy was the often 
used modality (n = 1766, 60%). Radiation was used in most 
of the patients (n = 1700, 57%). In the patients that received 
radiation, no other therapy was used in 23% of patients (n = 
383), whereas 63% of patients (n = 1065) received radiation 
with only chemotherapy and 2% of patients (n = 40) received 
radiation with only surgery, but only 12% of patients (n = 212) 
had all three treatment modalities.
Only a minority of patients had surgery (n = 709, 24%). 
Of the 709 patients for whom surgery was performed, 235 
patients (33%) had surgery alone, 40 patients (6%) had sur-
gery with radiation only, 222 patients (31%) had surgery with 
chemotherapy only, and 212 patients (30%) had all three treat-
ments. Of the 252 patients (8%) who received both surgery 
and radiation, 72 patients (28%) received preoperative radia-
tion, and 180 patients (72%) had postoperative radiation. Of 
the 434 patients who received both surgery and chemotherapy, 
most of the patients (n = 322, 74%) were given chemotherapy 
after surgery. The extent of surgery is listed in Table 2, along 
with the timing of other therapies for each specific surgical 
approach. Most patients who had surgery had a lobar resec-
tion (n = 563, 79%), whereas a minority had either a sublobar 
resection (n=50, 7%) or a pneumonectomy (n = 63, 9%).
The uses of PET scans and invasive staging modalities 
are summarized in Table 3. Overall, a PET scan was used for 
staging in 1615 patients (55%). Invasive mediastinal staging 
was done in 506 patients (17%). Patients who had surgery 
were more likely to have had invasive mediastinal staging 
compared with patients who did not have surgery. Compared 
with patients who received any therapy, patients who did not 
receive any therapy were less likely to have been staged with 
either a PET scan or with invasive mediastinal staging.
The characteristics of the patients who had and who did 
not have surgery are listed in Table 4. The factors that pre-
dicted the use of surgery in multivariate-adjusted analysis 
were younger age (p < 0.0001), lower T-stage (p < 0.0001), 
female sex (p = 0.04), and living in a census track with a 
higher median income (p = 0.03) (Table 5). The characteristics 
of the patients who had or did not have any therapy are also 
TABLE 1.  Treatments Used for 2958 Patients with Stage 
IIIA (N2) in the Surveillance, Epidemiology, and End Results 
–Medicare Database from 2004 to 2007
Treatment n
Trimodal therapy
 Surgery, radiation, and chemotherapy 212 (7%)
 Radiation before surgery 68 (2%)
  Chemotherapy before surgery 64 (2%)
  Chemotherapy after surgery 4 (0.1%)
 Radiation after surgery 144 (5%)
  Chemotherapy before surgery 11 (0.4%)
  Chemotherapy after surgery 133 (5%)
Bimodal therapy
 Radiation and chemotherapy 1065 (36%)
 Surgery and radiation 40 (1%)
  Radiation before surgery 4 (0.1%)
  Radiation after surgery 36 (1%)
 Surgery and chemotherapy 222 (8%)
  Chemotherapy before surgery 47 (2%)
  Chemotherapy after surgery 175 (6%)
Unimodal therapy
 Radiation alone 383 (13%)
 Surgery alone 235 (8%)
 Chemotherapy alone 267 (9%)
No therapy 534 (18%)
TABLE 2.  Extent of Surgery, along with Timing Related to Other Therapy, for 709 Patients with Stage IIIA (N2) in the 
Surveillance, Epidemiology, and End Results –Medicare Database Who Had Surgery
Lobar Resection  
(n = 563)
Sublobar Resection  
(n = 50)
Pneumonectomy  
(n = 63)
Local Treatment  
(n = 32)
Unknown Extent of  
Surgery (n = 1)
Surgery alone 178 (32%) 23 (46%) 24 (38%) 10 (31%) 0
Surgery, chemotherapy, and 
radiation
167 (30%) 15 (30%) 19 (31%) 11 (34%) 0
 Radiation presurgery 55 (10%) 2 (4%) 8 (13%) 3 (9%) 0
  Chemotherapy presurgery 54 (10%) 2 (4%) 7 (11%) 1 (3%) 0
   Chemotherapy 
postsurgery
1 (0.2%) 0 1 (2%) 2 (6%) 0
 Radiation postsurgery 112 (20%) 13 (26%) 11 (18%) 8 (25%) 0
  Chemotherapy presurgery 9 (2%) 1 (2%) 1 (2%) 0 0
   Chemotherapy 
postsurgery
103 (18%) 12 (24%) 10 (16%) 8 (25%) 0
Surgery and chemotherapy 191 (34%) 7 (14%) 17 (27%) 7 (22%) 0
 Chemotherapy presurgery 39 (7%) 1 (2%) 6 (10%) 1 (3%) 0
 Chemotherapy postsurgery 152 (27%) 6 (12%) 11 (17%) 6 (19%) 0
Surgery and radiation 27 (5%) 5 (10%) 3 (5%) 4 (12%) 1 (100%)
 Radiation presurgery 4 (1%) 0 0 0 0
 Radiation postsurgery 23 (4%) 5 (10%) 3 (5%) 4 (12%) 1 (100%)
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listed in Table 4. The only factor that predicted that patients 
did not receive any therapy in multivariate-adjusted analysis 
was older age (p < 0.0001) (Table 5).
The overall 3-year survival of all patients was 
21.8 ± 1.5% (Fig. 1A). Patients who had surgery had an over-
all 3-year survival of 42.1 ± 3.8%, whereas the overall 3-year 
TABLE 3.  Staging Modalities Used for 2958 Patients with Stage IIIA (N2) in the Surveillance, Epidemiology, and End Results–
Medicare Database from 2004 to 2007
 
Variable
All Patients  
(n = 2958)
Surgery  
(n = 709)
No Surgery  
(n = 2249)
 
p Value
Any Therapy  
(n = 2424)
No Therapy  
(n = 534)
 
p Value
Positron emission  
tomography scan
1615 (55%) 403 (57%) 1212 (54%) 0.7 1456 (60%) 159 (30%) <0.0001
Invasive staging 506 (17%) 201 (28%) 305 (14%) <0.0001 468 (19%) 38 (7%) <0.0001
TABLE 4.  Specific Characteristics of 2958 Patients with Stage IIIA (N2) in the Survival, Epidemiology, and  
End Results–Medicare Database from 2004 to 2007, Stratified by Both Whether Surgery Was Used or Not and Whether  
Any Therapy Was Used or Not
 
Variable
Surgery  
(n = 709)
No Surgery  
(n = 2249)
 
p Value
Any Therapy  
(n = 2424)
No Therapy  
(n = 534)
 
p Value
Age, yr <0.0001 <0.0001
 66–69 187 (26%) 421 (19%) 525 (22%) 83 (16%)
 70–74 224 (32%) 613 (27%) 703 (29%) 134 (25%)
 75–79 185 (26%) 576 (26%) 638 (26%) 123 (23%)
 80–84 92 (13%) 428 (19%) 398 (16%) 122 (23%)
 85+ 21 (3%) 211 (9%) 160 (7%) 72 (13%)
T-stage T1 <0.0001 0.02
 T2 203 (29%) 524 (23%) 620 (26%) 107 (20%)
 T3 453 (64%) 1367 (61%) 1476 (61%) 344 (64%)
 T3 53 (7%) 358 (16%) 328 (14%) 83 (16%)
Chemotherapy 0.35 <0.0001
 Yes 434 (61%) 1332 (59%) 1766 (73%) 0 (0%)
 No 275 (39%) 917 (41%) 658 (27%) 534 (100%)
Radiation therapy <0.0001 <0.0001
 Yes 252 (35%) 1448 (64%) 1700 (70%) 0 (0%)
 No 457 (65%) 801 (36%) 724 (30%) 534 (100%)
Sex 0.02 0.8
 Male 355 (50%) 1241 (55%) 1305 (54%) 291 (54%)
 Female 354 (50%) 1008 (45%) 1119 (46%) 243 (46%)
Race 0.001 0.5
 Black 37 (5%) 205 (9%) 202 (8%) 40 (7%)
 Nonblack 672 (95%) 2044 (91%) 2222 (92%) 494 (93%)
Charlson comorbidity index 0.06 0.4
 0 199 (28%) 562 (25%) 632 (26%) 129 (24%)
 1 176 (25%) 485 (22%) 553 (23%) 108 (20%)
 2 125 (18%) 436 (19%) 457 (19%) 104 (19%)
 3 80 (11%) 309 (14%) 309 (13%) 80 (15%)
 4+ 129 (18%) 457 (20%) 473 (20%) 113 (21%)
Census tract median income 53,501±24,954 47,759±21,422 <0.0001 49,719±22,968 46,491±19,726 0.003
Census tract % of black 7.4 ± 15.9 10.7 ± 21.1 <0.0001 9.6 ± 19.6 11.2 ± 21.8 0.11
Census tract % of people with 4 years 
of college education
28.0 ± 18.0 24.4 ± 16.4 <0.0001 25.7 ± 17.0 23.7 ± 16.0 0.02
Census tract % of people living below 
the poverty line
9.9 ± 8.6 11.8 ± 9.9 <0.0001 11.1 ± 9.5 12.5 ± 10 0.004
Continuous data are presented as mean ± SD.
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survival of patients who did not have surgery was 15.4 ± 1.5% 
(Fig. 1B). In the multivariate-adjusted Cox proportional haz-
ard regression model, factors that predicted worse survival 
were not having surgery, not having radiation therapy, not 
getting chemotherapy, increasing age, higher T-stage, and a 
Charlson comorbidity index of two or greater (Table 6).
When only patients who received local therapy with 
either surgery or radiation were included in the survival analy-
sis, the overall 3-year survival was 25.6 ± 1.9% (Fig. 1C). As 
above, patients who had surgery with or without radiation had 
an overall 3-year survival of 42.1 ± 3.8%. The overall 3-year 
survival of patients who only had radiation was 17.5 ± 2.0% 
(Fig. 1D). After multivariable adjustment, the risk factors that 
predicted worse survival were not having surgery, not getting 
chemotherapy, increasing age, higher T-stage, and Charlson 
comorbidity index of two or greater (Table 7). In this subset of 
patients, a tumor T-stage of T3 was the strongest predictor of 
worse survival (hazard ratios, 1.90; p < 0.0001).
DISCUSSION
In this study, we demonstrated that the treatment of 
elderly patients with stage IIIA (N2) NSCLC in the SEER-
Medicare database is highly variable. Radiation is used in 
most of the patients (57%), and the most common treatments 
are radiation with chemotherapy (36%), no treatment (18%), 
and radiation alone (13%). Surgical resection is used as part 
of the treatment regimen in only 24% of elderly patients. The 
use of surgery is dependent on patient-specific factors, such 
as age, tumor T-status, and comorbidities, but also socioeco-
nomic factors such as the median income of the census tract 
where patients live.
Stage IIIA (N2) accounts for a minority but still 
significant number of patients with lung cancer, considering 
that lung cancer is the most common cause of cancer-related 
mortality in the United States with over 222,000 new cases 
and over 157,000 deaths in 2010.1,2,35,36 The reported 5-year 
survival rates for stage IIIA (N2) vary from 15% to 42%.2,4,7,9,37 
Providing treatment that optimizes the chance for cure and 
minimizes morbidity is critical, and multimodality therapy 
with some combination of surgical resection, chemotherapy, 
and radiation therapy is generally considered the preferred 
approach.3 Both induction and adjuvant chemotherapy 
improve survival compared with surgical resection for 
patients with clinical stage IIIA based on suspected N2 
nodal involvement.4–7,38,39 However, the role of adding 
induction radiation therapy to chemotherapy, and even the 
role of surgery when radiation and chemotherapy have been 
used is unclear.8–10,40 Adding induction radiation therapy to 
induction chemotherapy has not been shown to give a survival 
benefit compared with induction chemotherapy alone in 
randomized controlled trials, phase II studies, or retrospective 
reviews.35,41–45 Induction chemotherapy and radiation therapy 
(45 Gy) followed by surgical resection for patients with stage 
IIIA disease has been demonstrated to be feasible, but did not 
improve survival compared with chemotherapy and radiation 
(61 Gy) without surgical resection in a randomized phase III 
TABLE 5.  Multivariable Models of Both the Use of Surgery and the Use of No Therapy for 2958 Patients with Stage IIIA (N2) in 
the Survival, Epidemiology, and End Results–Medicare Database from 2004 to 2007
Predictor
Outcome = Surgery Used Outcome = No Therapy Used
OR 95% CI p OR 95% CI p
Age, yr <0.0001 <0.0001
 70–74 vs. 66–69 0.82 0.65–1.04 1.2 0.88–1.62
 75–79 vs. 66–69 0.67 0.52–0.86 1.21 0.89–1.65
 80–84 vs. 66–69 0.45 0.33–0.60 1.93 1.40–2.65
 85+ vs. 66–69 0.24 0.15–0.39 2.67 1.82–3.92
T-stage <0.0001 0.07
 T2 vs. T1 0.91 0.74–1.12 1.28 1.00–1.64
 T3 vs. T1 0.42 0.30–0.59 1.42 1.02–1.98
Census tract % of people with  
4 years of college education
1 1.00–1.01 0.45 1 0.99–1.01 0.6
Census tract % of black 1 0.99–1.00 0.27 1 1.00–1.01 0.2
Charlson Comorbidity Index 0.24 0.44
 1 vs. 0 1.07 0.84–1.37 0.94 0.70–1.26
 2 vs. 0 0.83 0.63–1.09 1.03 0.76–1.39
 3 vs. 0 0.82 0.60–1.12 1.21 0.88–1.68
 4+ vs. 0 0.86 0.66–1.12 1.19 0.89–1.60
Census Tract Median Income 1 1.00–1.00 0.03 1 1.00–1.00 0.5
Race (black vs. nonblack) 0.7 0.45–1.10 0.12 0.68 0.43–1.09 0.11
Sex (male vs. female) 0.83 0.70–0.99 0.04 1.04 0.86–1.27 0.7
Census tract % of people living below  
the poverty line
1 0.98–1.01 0.8 1.01 0.99–1.02 0.32
CI, confidence interval.
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FIGURE 1. (A) Survival curve for 
all patients. (B) Survival curve for all 
patients stratified by surgery versus 
no surgery. (C) Survival curve for all 
patients who received either surgery 
or radiation. (D) Survival curve for all 
patients who received either surgery 
or radiation stratified by surgery vs. 
no surgery.
TABLE 6.  Multivariable Model of Survival for 2958 Patients 
with Stage IIIA (N2) in the Survival, Epidemiology, and  
End Results–Medicare Database from 2004 to 2007
Predictor Hazard Ratio p
Surgery (no surgery vs. surgery) 2.19 <0.0001
Radiation (no vs. yes) 1.17 0.0009
Chemotherapy (no vs. yes) 1.45 <0.0001
Age, yr
 70–74 vs. 66–69 1.17 0.01
 75–79 vs. 66–69 1.3 <0.0001
 80–84 vs. 66–69 1.39 <0.0001
 85+ vs. 66–69 1.4 0.0002
T-stage
 T2 vs. T1 1.49 <0.0001
 T3 vs. T1 2.1 <0.0001
Charlson Comorbidity Index
 1 vs. 0 1.08 0.2
 2 vs. 0 1.2 0.005
 3 vs. 0 1.25 0.002
 4+ vs. 0 1.36 <0.0001
TABLE 7.  Multivariable Model of Survival for 2157 Patients 
Treated with Either Surgery or Radiation for Stage IIIA (N2) 
in the Survival, Epidemiology, and End Results–Medicare 
Database from 2004 to 2007
Predictor Hazard Ratio p
Surgery (no surgery vs. surgery) 1.79 <0.0001
Radiation (no vs. yes) 0.85 0.13
Chemotherapy (no vs. yes) 1.43 <0.0001
Age, yr
 70–74 vs. 66–69 1.15 0.06
 75–79 vs. 66–69 1.2 0.01
 80–84 vs. 66–69 1.32 0.001
 85+ vs. 66–69 1.26 0.04
T-stage
 T2 vs. T1 1.44 <0.0001
 T3 vs. T1 1.9 <0.0001
Charlson Comorbidity Index
 1 vs. 0 1.09 0.26
 2 vs. 0 1.18 0.03
 3 vs. 0 1.2 0.04
 4+ vs. 0 1.37 <0.0001
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study.11 However, exploratory analysis in this randomized 
phase III study did suggest that surgical resection might 
convey some survival benefit over chemotherapy and radiation 
therapy alone in patients whose surgical resection consisted of 
lobectomy.11 In addition, subgroup analysis of the patients that 
underwent surgical resection demonstrated that patients who 
had pathological evidence of clearance of disease from their 
mediastinal lymph nodes after chemotherapy and radiation 
therapy had improved survival over patients who had persistent 
nodal disease despite chemotherapy and radiation therapy.
Given the lack of clear evidence to guide treatment, 
and that many studies have demonstrated potential benefit for 
several strategies, the results of this study demonstrating vari-
ability in the treatment of stage IIIA (N2) patients in a large 
national cohort are not necessarily unexpected. A significant 
number of patients (18%) did not receive any treatment at all, 
with patient age apparently being the most important factor 
in the treatment decision-making process in this setting. The 
use of surgery in only 24% of patients is not surprising, given 
the available evidence on the benefits of surgical resection. 
However, this study does show that certain variables are asso-
ciated with the use of surgery. The most powerful predictors 
for the use of surgery are patient and tumor specific, such 
as age and T-stage, and are likely at least in part predictors 
of patients who may not be medically or technically resect-
able. These findings suggest that the treatment used for many 
patients is appropriately chosen based on individual patient 
factors. However, nonmedical patient characteristics, notably 
related to the income level of the census tract where patients 
live, were also significant predictors for the use of surgery, 
although the association of this factor with surgery was much 
weaker than that of the important identified clinical factors. 
Interestingly, black race was important in predicting the use 
of surgery in univariate analysis but not multivariate analysis 
when other factors were considered.
These results are consistent with other studies that have 
demonstrated disparities in the incidence, treatment, and sur-
vival of lung cancer. Blacks have a higher incidence of lung 
cancer, undergo surgery less often, and have worse survival 
for resectable lung cancers compared with white patients.13–19 
However, stage-specific survival does not differ between 
blacks and whites if treatment strategy, comorbidities, patient 
functional status, and other potential confounding factors are 
considered.46,47 Socioeconomic status, educational status, and 
geography also contribute importantly to both the incidence 
of and the outcomes associated with lung cancer.13,20–26 Blacks 
and patients with low socioeconomic status are most likely to 
present with advanced disease at the time of diagnosis of lung 
cancer and are less likely to receive what would be considered 
the evidence-based standard therapy for all stages of lung can-
cer.14,48,49 Therefore, the observed disparities can most likely be 
explained by differences in the way lung cancer patients pres-
ent, are diagnosed, and ultimately treated. Considering that the 
results of the current study show that the treatment regimen 
used for stage IIIA (N2) NSCLC is dependent on the socio-
economic status of the census tract where patients live, part of 
the treatment variability could be because of differences in the 
ways patients in lower socioeconomic regions have access to, 
are offered, or choose therapy.
Although this study suggested a survival benefit to 
the use of surgery for stage IIIA (N2) NSCLC, the results 
cannot be construed as being definitive evidence of the 
advantage of surgery over other treatment regimens that do 
not include surgery. Even when patients are limited to the 
subset of stage IIIA because of N2 involvement, there is still 
potentially significant heterogeneity in the extent of nodal 
involvement. Mediastinal nodal involvement can vary from 
microscopic disease recognized on pathologic examination 
after resection or unexpectedly at the time of resection, to 
nonbulky single station or multistation mediastinal lymph 
node metastases recognized and proven before any treatment, 
or bulky multistation N2 disease.3 These pathologic details 
are not available in the SEER-Medicare database, and the 
improved outcomes seen with surgery could possibly be due 
to the preferential use of surgery with more limited nodal 
involvement. In addition, SEER-Medicare does not contain 
information on other important clinical variables, including 
a patient’s overall functional status, pulmonary function data, 
and smoking status. Surgery may have been preferentially 
selected for patients with better functional status, better 
pulmonary function, and less significant current and past 
smoking use, which are all factors that can impact both 
treatment selection and outcomes such as survival.
This study does have other limitations, including 
its retrospective nature and reliance on an administrative 
database in which some data may be missing. The data only 
include patients aged 65 years or older, and these results may 
not be generalizable to younger patients with lung cancer. 
Also, including a comorbidity index is helpful in limiting the 
impact of selection bias based on comorbid conditions, but 
the comorbidity index does not guarantee that the acuity and 
severity of comorbid conditions are well balanced between 
the different groups evaluated. Also, all patients in this study 
had insurance coverage through Medicare, and therefore 
the results are not necessarily generalizable to a population 
of patients that include uninsured or underinsured patients. 
Finally, given that SEER did not record details on N status 
until 2004 and includes follow-up only until 2007, the overall 
follow-up period for the patients in the study is relatively 
short. However, use of the population-based SEER-Medicare 
database has the significant advantage of allowing evaluation 
of a large number of patients with an uncommon disease 
stage. The expense and complexity of enrolling patients and 
performing a study that involves both a relatively uncommon 
disease stage and potentially a major surgical procedure make 
it unlikely that a prospective study could ever accumulate 
anywhere near the number of patients that are available for 
analysis in this database.
In conclusion, stage IIIA (N2) NSCLC represents a het-
erogeneous group of patients for which the optimal treatment 
is not well established. Treatment of elderly patients with this 
stage of disease is highly variable in the United States and 
varies with age, T-stage, and socioeconomic factors of the 
area where patients live. Before initiating treatment, multi-
disciplinary evaluation of all patients with this stage of lung 
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cancer with appropriate consideration of all potential treat-
ment options may limit variability in care such that only 
patient and tumor-specific factors drive the choice of therapy, 
which may optimize outcomes while avoiding treatment-
related morbidity.
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